Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1433076 | 0.79 | MAPT (0.49) | FPR3FPR2 | |
| SCHEMBL4893197 | 0.79 | FNTA (0.45) | FNTAFNTBPGGT1BFPR3FPR2 | |
| SCHEMBL29066264 | 0.74 | CKS1B (0.49) | FPR3FPR2 | |
| SCHEMBL8204606 | 0.72 | TAAR1 (0.73) | TAAR1 | |
| SCHEMBL4894114 | 0.72 | TAAR1 (0.47) | FNTAFNTBPGGT1BTAAR1 | |
| SCHEMBL19816492 | 0.71 | QPCT (0.55) | — | |
| SCHEMBL24329996 | 0.69 | TMEM97 (0.48) | FPR3FPR2 | |
| SCHEMBL20313968 | 0.69 | MTNR1A (0.54) | — | |
| SCHEMBL3162868 | 0.69 | TAAR1 (0.54) | TAAR1 | |
| SCHEMBL9573408 | 0.69 | HRH3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | UNIVERSITY OF WASHINGTON (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2006102159-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA AND CANCER | YALE UNIVERSITY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | AKR1C3, NR1H3, HCCS | SSTR4 1959/4885GBA1 1466/4885FNTA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.